ArticlePloS one2026
YTHDF1 impacts cardiomyocyte differentiation by regulating the TET2 mRNA.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiac diseases frequently arise from compromised cardiomyocyte differentiation and function. Although studies have demonstrated that loss of the m6A modification reader YTHDF1 impairs cardiomyocyte differentiation, the specific mRNA transcripts it directly regulates remain to be identified. Comprehensive analysis of public databases was conducted to examine the correlation between YTHDF1 expression and cardiac differentiation processes as well as specific cardiac pathology. Stable YTHDF1-knockdown cell lines were generated in the rat H9C2 cardiomyoblasts. After retinoic acid (RA) induction, cardiomyocyte differentiation was assessed. RNA immunoprecipitation sequencing (RIP-seq) was performed in H9C2 cells, and the resulting data were integrated with known cardiomyocyte differentiation regulators to identify direct YTHDF1 mRNA targets. Here we found that YTHDF1 expression increases progressively during cardiomyocyte differentiation but gradually declines upon cellular/organ maturation in mice. Human left ventricle (LV) exhibited higher YTHDF1 expression than right ventricle (RV), while LV from dilated cardiomyopathy (DCM) patients showed modestly reduced YTHDF1 levels compared to healthy controls. In differentiating H9C2 cardiomyoblasts, YTHDF1 expression progressively increased. YTHDF1 knockdown impaired differentiation, reducing maturation markers cTnT/cTnI, which was aligned with RNA-seq analysis. RIP-seq identified significant TET2 mRNA enrichment in YTHDF1 complexes. YTHDF1 knockdown selectively reduced TET2 protein level without affecting its mRNA level, while YTHDF1 overexpression enhanced TET2 translation. Additionally, we identified a novel rat tet2 variant. Complementation with this variant in YTHDF1-knockdown H9C2 cells rescued the differentiation defect. Collectively, YTHDF1 promotes cardiomyocyte differentiation by regulating TET2 mRNA during cardiac development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.